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Abstract A differential display technique was used to identify
androgen-regulated genes in LNCaP prostatic adenocarcinoma
cells. One of the genes markedly upregulated by androgens
proved to be identical to differentiation-related gene 1 (Drg1 ;
also described as RTP, Cap43 and rit42), a gene whose
expression has recently been shown to be diminished in colon,
breast and prostate tumors. We show that Drg1 is abundantly
expressed in the (androgen-exposed) human prostate and that its
expression is stimulated some 14-fold in androgen-treated
LNCaP cells. The ligand specificity of the induction reflects
the altered specificity of the mutated androgen receptor in
LNCaP. In androgen receptor negative tumor lines basal
expression is slightly higher than in LNCaP but inducibility is
absent. These data suggest that Drg1 is a novel marker of
androgen-induced differentiation in the human prostate.
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1. Introduction
Androgens play a pivotal role both in the development of
the normal prostate and in the pathogenesis of benign pro-
static hyperplasia and prostate cancer, diseases which become
increasingly prevalent in our aging Western society [1,2]. Ini-
tial studies on the e¡ects and mechanism of action of andro-
gens in the human prostate have focused on secreted proteins
such as prostate-speci¢c antigen (PSA) [3]. It is becoming
increasingly clear, however, that many other prostatic proteins
and functions are under androgenic control [4,5]. We have
used a di¡erential display technique to characterize more fully
the response of LNCaP prostatic adenocarcinoma cells to
androgens [6]. Here we identify one of the PCR fragments
upregulated by androgens as Drg1. Initially the only sequence
found to be homologous to this fragment was a mouse gene
known as Ndr1 (N-myc downstream regulated gene 1; A.
Shimono and H. Kondoh; GenBank acc. no. U60593), a
gene isolated by subtraction hybridization between wild-type
mouse embryo and mouse embryo carrying an N-myc dele-
tion. The homologous human cDNA has since then be iden-
ti¢ed in a variety of independent studies also based on the use
of di¡erential display. In a ¢rst report the corresponding gene
was termed RTP (reducing agents and tunicamycin-responsive
protein [7]), a homocysteine-respondent gene in vascular en-
dothelial cells. Shortly thereafter it was identi¢ed as a di¡er-
entiation marker of colon epithelial cells, downregulated in
colorectal neoplasms (Drg1 ; di¡erentiation-related gene 1
[8]). Very recently an Ni2-induced gene in lung A549 cells
(Cap43 [9]) and a p53-responsive gene with antiproliferative
properties (RTP/rit42 [10]) proved highly homologous or
identical to RTP and Drg1. In the mean time the mouse
gene has also been cloned and characterized as TDD5, a
gene di¡erentially repressed by testosterone and 5K-dihydro-
testosterone (DHT) in a T cell hybridoma [11]. The potential
role of the human homologue of Ndr1, further conveniently
referred to as Drg1, as a di¡erentiation marker and its indu-
cibility in a variety of tumor cell lines by apparently unrelated
factors stimulated us to explore its response to androgens in
LNCaP cells in more detail.
2. Materials and methods
2.1. Cell culture and androgen treatment
The human prostatic adenocarcinoma cell lines LNCaP [12], PC-3
[13] and DU-145 [14] and the breast cancer cell line T47D were pur-
chased from the American Type Culture Collection (Manassas, VA,
USA). Cells were maintained in a humidi¢ed atmosphere of 5% CO2
in air in RPMI-1640 medium (LNCaP, T47D) or in DMEM (PC-3
and DU-145) supplemented with 10% fetal calf serum (FCS), 3 mM L-
glutamine, 100 Wg/ml streptomycin and 100 U/ml penicillin (all from
Life Technologies Inc., Paisley, Scotland) and for T47D: insulin 5 Wg/
ml. To examine the e¡ects of steroids, cells were preincubated for 2^3
days in RPMI-1640 medium containing 5% FCS pretreated with dex-
tran-coated charcoal (CT-FCS) as previously described [15]. The two
recently developed androgen sensitive prostate tumor lines MDA
PCa-2a and -2b were kindly provided by Dr. N. Navone and were
maintained as described [16]. Androgen responsiveness was evaluated
in F-12K medium supplemented with 15% CT-FCS. Natural steroids
and dexamethasone were purchased from Sigma Chemical Co (St.
Louis, MO, USA). R1881 (methyltrienolone) and mibolerone were
obtained from Dupont-New England Nuclear (Boston, MA, USA).
Steroids were dissolved in absolute ethanol. Control cultures received
similar amounts of ethanol only. Final ethanol concentrations did not
exceed 0.1% (v/v).
For the actinomycin D (Sigma Chemical Co., St. Louis, MO, USA)
experiment, cells were preincubated for 2 days in RPMI-1640 medium
containing 5% CT-FCS, before incubation with fresh medium con-
taining 5 Wg/ml actinomycin D for the indicated periods of time.
2.2. mRNA di¡erential display and DNA sequencing analysis
The mRNA di¡erential display polymerase chain reaction (DD-
PCR, [17]) was performed using a kit provided by Display Systems
(Tandill Ltd, LA, USA) as described earlier [6].
DNA sequencing was performed using Autoread sequencing kits
(Pharmacia, Uppsala, Sweden) and an A.L.F. automated sequencer
(Pharmacia). The sequences of both strands were determined. Sequen-
ces were analyzed using the GCG Wisconsin package provided
through the services of the Belgian Embnet Node (BEN). Comparison
of DNA homology with the EMBL and the GenBank databases was
performed using BLAST [18] and FASTA [19] routines.
2.3. Northern and dot blot analysis
Northern and dot blot hybridizations were carried out as previously
described [15]. A radiolabelled Drg1 cDNA probe was prepared as
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follows. The 311 bp DD-PCR fragment (cloned into pGEM-T plas-
mid; Promega, Madison, WI, USA) was ¢rst ampli¢ed by PCR using
pUC/M13 forward and reverse sequencing primers (Pharmacia, Up-
psala, Sweden). Approximately 20 ng of the PCR product was used in
a radiolabelling reaction mixture (total volume: 12 Wl) containing
10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 15 WCi
[K32P]-dCTP (3000 Ci/mmol, Amersham International, Buckingham-
shire, UK), 50 WM each of dATP, dTTP and dGTP, 0.4 WM 10-mer
primer 5P-TGGATTGGTC-3P, 0.4 WM dT11CG primer and 0.025 U/Wl
Taq DNA polymerase. PCR cycling conditions were as described for
di¡erential display analysis [6]. A radiolabelled 18S probe was pre-
pared as described earlier [20]. Hybridization signals were quanti¢ed
using PhosphorImager screens (Molecular Dynamics, Sunnyvale, CA,
USA).
3. Results
3.1. Identi¢cation of Drg1 as an androgen-induced gene
One of the DD-PCR bands that was reproducibly induced
after treatment of LNCaP cells with 1038 M of the synthetic
androgen R1881 was a 311 bp cDNA fragment detected with
the 10-mer primer 5P-TGGATTGGTC-3P and the oligo-dT
primer dT11CG (data not shown). This fragment proved
70.4% homologous with the 3P untranslated region of the
mouse Ndr1 cDNA (A. Shimono and H. Kondoh; GenBank
acc. no. U60593: bp 2585^2897). During our attempts to se-
quence the homologous human cDNA, the corresponding se-
quence was reported by various groups [7^10]. The homology
of our 311 bp PCR fragment with these sequences was 97%
and a similar homology was observed for the other cDNA
sequences available from our laboratory (approximately
1.5 kb) suggesting that the isolated genes were most likely
identical.
3.2. Androgen regulation of Drg1 expression in LNCaP cells
Northern blots prepared from LNCaP cells treated or not
with androgens were used to study the regulation of Drg1
expression in more detail. The 311 bp cDNA fragment was
used as a probe. Dose response curves with R1881 revealed a
classical hyperbolic pro¢le (Fig. 1A). Maximal stimulation
was observed from a concentration of 1039 M on. In a series
of independent measurements at 1038 M R1881 the mean
degree of stimulation was 14 þ 3 (mean þ S.D.; n = 8). More-
over, the size of the Drg1 mRNA in LNCaP cells (about
3.0 kb) matched that reported for the corresponding mouse
and human transcripts (Figs. 2 and 3). Induction became evi-
dent after 8^16 h of treatment and culminated after 24 h (Fig.
1B). Thereafter, the level of Drg1 mRNA decreased.
The ligand speci¢city of the induction re£ects the altered
speci¢city of the mutated androgen receptor, characteristic for
LNCaP cells [21]. Optimal induction was observed with the
synthetic androgens R1881 and mibolerone. The natural and
rapidly metabolized androgens 5K-dihydrotestosterone (DHT)
and testosterone [22] were somewhat less active (Fig. 1C).
Progesterone and estradiol also displayed stimulatory e¡ects.
Glucocorticoids were inactive.
Actinomycin D (5 Wg/ml) completely prevented androgen
induction of Drg1 mRNA after 16 and 24 h, underlining
the need for active RNA synthesis (data not shown). To de-
termine whether induction of Drg1 mRNA requires protein
synthesis, androgen stimulation was compared in the presence
and absence of the protein synthesis inhibitor cycloheximide.
At a concentration (1 Wg/ml) that clearly prevents stimulation
of other androgen-regulated genes such as DBI/ACBP [15],
cycloheximide decreased basal expression but did not prevent
androgen induction (Fig. 2), suggesting that androgen induc-
tion of Drg1 mRNA does not depend on the synthesis of
intermediary proteins.
3.3. Drg1 expression in other cell lines and tissues
To explore the relationship between Drg1 expression, an-
Fig. 1. Androgen dose-dependence (A), time course (B) and steroid
speci¢city (C) of Drg1 mRNA induction in LNCaP. After incuba-
tion for 48 h in medium containing 5% CT-FCS, medium was
changed and LNCaP cells were incubated with di¡erent concentra-
tions of R1881 for 72 h (A), in the absence (open bars) or in the
presence (hatched bars) of 1038 M R1881 for the indicated periods
of time (B), or for 72 h with 1038 M of the indicated steroids (C).
RNA was extracted for dot blot hybridization with a radiolabelled
Drg1 probe. Hybridization signals were quanti¢ed using Phosphor-
Imaging screens, and mRNA levels were expressed as relative densi-
tometric units, taking the value of vehicle-treated cells as 1.
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drogen responsiveness and degree of di¡erentiation, we also
studied basal and androgen-induced expression in two poorly
di¡erentiated androgen receptor negative cell lines, PC-3 [13],
and DU-145 [14] and in two recently developed androgen
receptor positive cell lines (MDA PCa-2a and -2b, [16]). As
illustrated in Fig. 3A, PC-3 and DU-145 cells displayed higher
basal levels of Drg1 mRNA than LNCaP cells but treatment
with 1038 M R1881 did not result in any further stimulation.
The MDA cell lines also displayed higher basal expression
levels but in these lines a clear response to androgens re-
mained evident (Fig. 3B). The extent of this response, how-
ever, was more limited than that observed for LNCaP. Higher
basal expression levels and a more limited response to andro-
gens were also observed for other androgen-responsive genes
in these cell lines (e.g. PSA; data not shown). Interestingly,
Drg1 expression was also stimulated by R1881 in the breast
carcinoma cell line T47D (Fig. 3B).
Northern and dot blot hybridization was used to analyze
Drg1 expression in di¡erent human tissues. Northern hybrid-
ization of a limited number of tissues (spleen, thymus, pros-
tate, testis, ovary, small intestine, colon, leukocytes) yielded
data identical to those reported previously [8], including very
high expression in the prostate (data not shown). A broader
screening using a dot blot containing normalized amounts of
poly(A) RNA from 50 di¡erent human tissues revealed ubiq-
uitous expression with highest levels in prostate followed by
spinal cords substantia nigras (fetal) kidneys subthalamic
nucleis uterussmedulla oblongata, thalamus, putamens
mammary glands thyroid gland and placenta (data not
shown).
4. Discussion
Using a di¡erential display technique we identi¢ed Drg1 as
an androgen-induced gene in LNCaP prostatic adenocarcino-
ma cells. The degree of induction (some 14-fold) is remarkably
high. Moreover, comparison of the mRNA expression level in
some 50 human tissues revealed the (androgen-exposed) pros-
tate as the organ with the highest level of expression, con¢rm-
ing previous observations on a more restricted number of
tissues [8]. Several intriguing points should be noticed. (1)
Drg1 (RTP, Cap43, rit42) and its mouse homologue (Ndr1,
TDD5) were identi¢ed in a variety of experimental settings
using di¡erential display [7^11]. The likely explanation is
that this gene, despite its ubiquitous expression, is not just a
housekeeping gene but that it is subject to marked changes in
transcript levels provoked by distinct regulatory factors (re-
ducing agents, tunicamycin, Ni2, p53, etc.) and that, cer-
tainly under stimulated conditions, expression is relatively
abundant. The gene appears to be evolutionary well conserved
and the limited di¡erences in the reported human sequences
can probably be explained by allelic variation. (2) In LNCaP
cells Drg1 is upregulated by androgens whereas in a mouse T
cell hybridoma and in mouse kidney the homologous gene is
downregulated [11]). The response in LNCaP cells is clearly
mediated by the androgen receptor as illustrated by the ligand
speci¢city (re£ecting the altered speci¢city of the mutated an-
drogen receptor in LNCaP [21]), the presence of a response in
two other androgen receptor positive prostate tumor lines,
and the absence of such a response in the receptor negative
tumor lines PC-3 [13] and DU-145 [14]. The exact mechanism
of gene activation requires further investigation. The fact that
actinomycin D blocks induction is compatible with transcrip-
tional control (as also reported in [9]). The ¢nding that cyclo-
heximide reduces basal transcript levels but does not prevent
androgen induction resembles earlier observations with PSA
and suggests that induction may be direct [15]. Studies on the
Drg1 promoter are in progress to analyze its regulation in
more detail. It should be noted that the e¡ects of androgens
in LNCaP become manifest after a relatively long latent peri-
od (8^16 h) as compared to those of all the other inducers
described higher (2^4 h). This probably means that several
distinct signaling pathways are able to activate Drg1 expres-
sion. (3) Earlier data have suggested that Drg1 may be a
di¡erentiation marker downregulated in colorectal neoplasms
but also in breast and prostate cancers [8,10]. The present
data demonstrate that in prostate tumors Drg1 expression
Fig. 3. Expression and androgen regulation of Drg1 in androgen re-
ceptor-positive and -negative human cell lines. Drg1 expression in
androgen receptor-positive LNCaP cells as compared to (A) andro-
gen receptor-negative cells PC-3 and DU-145, and (B) androgen re-
ceptor-positive cells T47D, MDA PCa-2a and -2b. Cells were cul-
tured for 3 days in medium supplemented with 5% (or 15% for
MDA PCa-2a and -2b) CT-FCS. Medium was changed and cells
were incubated in the absence (3) or in the presence (+) of 1038 M
R1881. After 3 days of treatment, Northern blot analysis was per-
formed as described in Fig. 2.
Fig. 2. E¡ects of cycloheximide on the induction of Drg1 mRNA
by R1881 in LNCaP cells. LNCaP cells were cultured for 48 h in
medium containing 5% CT-FCS. Medium was changed and cells
were incubated for another 24 h without (3) or with (+) 1038 M
R1881, either in the absence (3) or in the presence (+) of 1 Wg/ml
cycloheximide. Twenty Wg/lane of total RNA was separated on a
denaturing 1% agarose gel, transferred to a nylon membrane and
hybridized with a 32P-labelled Drg1 probe (top panel). The positions
of Drg1 mRNA and 18S and 28S ribosomal RNAs are indicated.
After removal of the probe, the blot was rehybridized with a radio-
labelled 18S rRNA probe to demonstrate that similar amounts of
RNA were present in all lanes (bottom panel).
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may at least in part re£ect androgen responsiveness. More-
over, they show that in poorly di¡erentiated tumor cells Drg1
expression is not completely lost and that basal levels of ex-
pression may even be increased. Further studies will be re-
quired to de¢ne the role of Drg1 in the normal prostate and
in prostate cancer. The ¢nding that expression in LNCaP cells
is maximal at concentrations of R1881 which promote di¡er-
entiation and reduce proliferation (s 1039 M), rather than at
low androgen levels that are optimal for proliferation (10310
M) [23^26], is compatible with a growth inhibitory role ob-
served in other systems [10]. Whether this relationship is cas-
ual or causal, however, remains to be investigated.
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